Navigation Links
Arena Pharmaceuticals Announces First Quarter 2009 Financial Results
Date:5/11/2009

SAN DIEGO, May 11, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported financial results for the first quarter ended March 31, 2009.

Arena reported a net loss allocable to common stockholders in the first quarter of 2009 of $50.6 million, or $0.68 per share, compared to a net loss allocable to common stockholders in the first quarter of 2008 of $55.0 million, or $0.75 per share.

"Receiving the positive lorcaserin BLOOM results was a significant milestone for Arena, and we are focusing our financial, management and development resources on completing the lorcaserin BLOSSOM trial on schedule and submitting our New Drug Application for lorcaserin by the end of the year," stated Jack Lief, Arena's President and Chief Executive Officer. "Given the challenging economic environment, we made the difficult decision to reduce the number of employees and limit our research programs to provide additional financial flexibility for this primary objective."

"As previously announced, during the first year of the BLOOM trial, 47.5% of lorcaserin patients lost 5% or more of their body weight from baseline, compared to 20.3% in the placebo group, exceeding the efficacy benchmark in the most recent FDA draft guidance," stated William R. Shanahan, M.D., Arena's Vice President and Chief Medical Officer. "Patients on lorcaserin rapidly lost a medically important amount of weight in a well-tolerated manner, with about one-third losing at least 5% of their body weight in only eight weeks. Lorcaserin helped nearly half of the patients to lose at least 5% of their body weight, and nearly a quarter to lose 10% or more of their body weight. We look forward to presenting these and additional data at the upcoming American Diabetes Association meeting in June."

As expected, research and deve
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009
2. Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million
3. Arena Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
4. Arena Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference
5. Arena Pharmaceuticals to Report Third Quarter 2008 Financial Results and to Host Conference Call and Webcast on Thursday, October 30, 2008
6. Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
7. Arena Pharmaceuticals to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
10. Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
11. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Woodstock, Vt. (PRWEB) August 28, 2014 ... microbiology testing around the world is available from ... industrial diagnostics companies. “ Industrial Microbiology Market Review, ... the Industrial Market ” (IMMR—4) tracks and compares ... in in North America, Europe and Asia, and ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Whitehouse Laboratories ... long term partnership with PTI Inspection Systems ... with state of the art leak testing method development ... art instruments currently available. As part of this agreement, ... High Voltage Leak Detection Instrument developed and manufactured ...
(Date:8/27/2014)... Livermore, California (PRWEB) August 27, 2014 ... (LLNL), through Lawrence Livermore National Security ... million to develop and deliver a state-of-the-art laser ... Beamlines facility (ELI Beamlines), under construction in the ... design performance, the laser system, called the " ...
(Date:8/27/2014)... TX (PRWEB) August 27, 2014 The ... and in-depth study on the current state of the ... report provides a basic overview of the industry, including ... and Chinese domestic market analysis are provided with a ... the market. A comparison between the international and Chinese ...
Breaking Biology Technology:2 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2
... New insights into why and how nanowires take the ... development of future electronic components. PhD student Peter Krogstrup ... is behind the sensational new theoretical model, which is ... One of the most important components in ...
... March 28, 2011 GeneWize Life ... GeneLink, Inc. (OTCQB: GNLK), has announced the world,s ... individual,s DNA and the first gene-modulating weight management supplement ... Starting on March 12, GeneWize distributors were ...
... March 28, 2011 BioMarin Pharmaceutical Inc. ... that Jean-Jacques Bienaime, Chief Executive Officer of ... webcast on Thursday, April 28, at 5:00 ... financial results.U.S. / Canada Dial-in Number:  888.396.2386International ...
Cached Biology Technology:Major advance in understanding how nanowires form 2GeneWize Expands DNA Customization into 3 Mega Markets 2GeneWize Expands DNA Customization into 3 Mega Markets 3BioMarin to Host First Quarter 2011 Financial Results Conference Call and Webcast on Thursday, April 28 at 5:00 p.m. ET 2
(Date:8/28/2014)... and mould in homes could pose a significant health risk ... in the Journal of Allergy and Clinical Immunology . ... eight different countries, the research has found that the presence ... in asthma sufferers, as well as increasing the likelihood of ... a team at the University of Exeter Medical School and ...
(Date:8/28/2014)... assigned a number of 435-million-year-old fossils to a ... in shallow marine habitats and were far less ... , Before they sank to the bottom ... some 435 million years ago, these arthropods preyed ... although they were not exactly inconspicuous, possessing a ...
(Date:8/27/2014)... Most of North America,s megafauna mastodons, short-faced bears, ... horses disappeared close to 13,000 years ago at ... this massive extinction has long been debated by scientists ... , A group of scientists, including UC Santa Barbara,s ... Science, posited that a comet collision with Earth played ...
Breaking Biology News(10 mins):Indoor mold poses health risk to asthma sufferers 2Paleontology: Oldest representative of a weird arthropod group 2Nanodiamonds are forever 2Nanodiamonds are forever 3
... 50 years as one of the most effective treatments ... been entirely sure exactly how it operates in the ... scientists suggests a mechanism for how Lithium works, opening ... tests on cells have shown that Lithium affects a ...
... 3 The General Services Administration (GSA) has ... provider of Personal Identity Verification (PIV) Enrollment and ... Security Presidential Directive 12 (HSPD-12). With this certification, ... 70 contract under the GSA SIN 132-62 as ...
... Authentication, Self-Service Check In, Credit Card Scanning and Patient ... PracticesCHICAGO and SUNNYVALE, Calif., April 7 ... Fujitsu , a leading provider of ... the Allscripts Patient Kiosk (TM), the ...
Cached Biology News:ABBTECH Staffing Services Certified by GSA as an HSPD-12 Managed Service Provider 2Allscripts Integrates Electronic Health Records with Innovative Patient Kiosk 2Allscripts Integrates Electronic Health Records with Innovative Patient Kiosk 3Allscripts Integrates Electronic Health Records with Innovative Patient Kiosk 4Allscripts Integrates Electronic Health Records with Innovative Patient Kiosk 5Allscripts Integrates Electronic Health Records with Innovative Patient Kiosk 6Allscripts Integrates Electronic Health Records with Innovative Patient Kiosk 7
Phospho-CD18 (Ser756/Thr758/759) Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Goat polyclonal to SART1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: GSSKKHRGEKEAA, corresponding to N terminal amino acids 2-14 of Human SART1. Entrez Gene ID: 909...
Phospho-Cyclin D1 (Thr286) Antibody...
STX18 Immunogen: STX18 (NP_058626, 101 a.a. ~ 200 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: